A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy. (VIDEO)

InSilico Medicine

Caption

Using an AI-driven robotics laboratory , the team identified INS018_055 (Rentosertib) —a potent small-molecule TNIK previously developed by Insilico Medicine, which has already advanced into clinical trials for idiopathic pulmonary fibrosis (IPF)—as a highly effective senomorphic agent capable of mitigating cellular senescence.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.